Categories Earnings, Health Care

AstraZeneca (NYSE: AZN): Q4 2019 Earnings Snapshot

— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.

— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.

— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.

— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.

— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.

— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top